Literature DB >> 30429028

Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.

Shuyuan Wang1, Bo Zhang1, Jie Qian1, Rong Qiao1, Jianlin Xu1, Lele Zhang1, Yiming Zhao1, Yanwei Zhang1, Rui Wang2, Ruiying Zhao3, Baohui Han4.   

Abstract

BACKGROUND: Lymphovascular invasion (LVI) and Visceral Pleural Invasion (VPI) have been reported to be risk factors for stage I Non-Small Cell Lung Cancer (NSCLC). However, only VPI was incorporated into the current 8th Tumor-Node-Metastasis (TNM) classification. This study aimed to explore the prognostic effect of LVI and VPI on TNM staging in pathological stage I NSCLC.
METHOD: We retrospectively reviewed 2633 consecutive p-stage I NSCLC patients in the Shanghai Chest Hospital (2008-2012). By using the Kaplan-Meier method and Cox proportional hazard regression model, we identified the correlations between LVI, VPI, and clinical outcomes in p-stage 1 NSCLC.
RESULTS: Of all 2633 p-stage I NSCLC patients, 222 were pathologically diagnosed with LVI and 836 pathologically with VPI. The 5-year recurrence free survival (RFS) and overall survival (OS) rates of patients with LVI was significantly worse compared to those without LVI (61.2% vs 82.0%, p < 0.001; 73.3% vs 88.1%, p < 0.001). The same results emerged for patients with VPI (70.1% vs 85.9%, p < 0.001; 82.3% vs 90.0%, p < 0.001). Using the univariable and multivariable analysis, we found that when tumor diameter was 3 cm or smaller, LVI (RFS: hazard ratio [HR], 2.54; 95% confidence interval [CI], 1.86-3.50; p < .001; OS: HR, 2.53; 95% CI, 1.72-3.71; p < .001) and VPI (RFS: HR, 2.14; 95% CI, 1.71-2.67; p < .001; OS: HR, 1.56; 95% CI, 1.12-2.04; p = 0.01) were significant prognostic factors for RFS and OS. When tumor size was between 3-4 cm, LVI (HR, 1.84; 95% CI, 1.03-3.29; p = 0.039) and VPI (HR, 2.56; 95% CI, 1.61-4.07; p < .001) were associated with inferior OS.
CONCLUSIONS: The presence of LVI significantly affected OS and RFS in stage I NSCLC patients. Our results suggested that it might be better to incorporate LVI as a T descriptor as VPI in the further TNM classification.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymphovascular invasion; Non-small cell lung cancer; Stage I; TNM classification; Visceral pleura invasion

Mesh:

Year:  2018        PMID: 30429028     DOI: 10.1016/j.lungcan.2018.09.024

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  Intratumoral lymph vessel invasion as a predictive risk factor for nodal metastasis in non-small cell lung cancer: should L-1 status obligate adjuvant chemotherapy?

Authors:  Kimberly J Song; Raja M Flores
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Biomarker Potential of Preoperative Tumor Size in Determination of the Lymphovascular Invasion in Squamous Cell Lung Cancer and Lung Adenocarcinoma.

Authors:  Kemal Grbic; Aida Mujakovic; Orhan Lepara; Zahid Lepara; Edin Begic; Ferid Krupic
Journal:  Int J Appl Basic Med Res       Date:  2021-04-08

3.  The Study of Tumor Volume as a Prognostic Factor in T Staging System for Non-Small Cell Lung Cancer: An Exploratory Study.

Authors:  Bei Jia; Xu Zhang; Yunxian Mo; Biao Chen; Hao Long; Tiehua Rong; Xiaodong Su
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

4.  The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.

Authors:  Yu Ma; Xi Yao; Zhenzhen Li; Jie Chen; Wensheng Li; Hongtao Wang; Lanjun Zhang; Jianfei Zhu
Journal:  World J Surg Oncol       Date:  2022-01-10       Impact factor: 2.754

5.  Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy.

Authors:  Wei Nie; Guangyu Tao; Zhenghai Lu; Jie Qian; Yaqiong Ge; Shuyuan Wang; Xueyan Zhang; Hua Zhong; Hong Yu
Journal:  J Transl Med       Date:  2022-07-28       Impact factor: 8.440

Review 6.  [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].

Authors:  Chen Shen; Wentao Fang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-08-20

7.  Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer.

Authors:  Jing-Sheng Cai; Xun Wang; Fei Yang; Yun Li; Man-Tang Qiu
Journal:  Thorac Cancer       Date:  2022-06-07       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.